IP Library Granted Patent US 11,034,966
Granted Patent B2
US 11,034,966 · App. 15/506,342 · Granted Jun 15, 2021

Patent

Inventors: Andrew Bristol (Rockville, MD); Michael Kaleko (Rockville, MD); Steven Hubert (Rockville, MD)
Assignee: Synthetic Biologics, Inc.
C12N15/70C12N9/86C12N15/67C12P21/02C12Y305/02006C12N15/09C12N15/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,034,966
App. No.
15/506,342
Granted
Jun 15, 2021
Kind
B2
Abstract

The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli ( E. coli ) cells. High yield production of beta-lactamase is achieved using methods of the invention.

Claims (22)

1. A method for the production of a beta-lactamase polypeptide in Escherichia coli ( E. coli ), comprising:

(a) providing a host E. coli cell transformed with an expression vector comprising a sequence encoding the beta-lactamase polypeptide;

(b) culturing the E. coli cell to induce expression of the beta-lactamase polypeptide in the cytoplasm; and

(c) recovering the beta-lactamase polypeptide from a cytoplasmic soluble fraction prepared from the E. coli cell; and

wherein the method yields more than 10 grams of the beta-lactamase polypeptide per liter of

culture,

wherein the beta-lactamase polypeptide comprises an amino acid sequence having at least 95% identity with a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 10,

wherein the host E. coli cell is selected from BL21 (DE3) or W3110, and

wherein the beta-lactamase polypeptide is not recovered or purified from a periplasmic fraction, a cell envelope fraction, a cytoplasmic insoluble fraction, an inclusion body, or an extracellular fraction of the E. coli cell.

2. The method of claim 1 , wherein the method yields more than 15 grams of the beta-lactamase polypeptide per liter of culture.

3. The method of claim 1 , wherein expression of the beta-lactamase polypeptide in the cytoplasm is induced by adding isopropylthiogalactoside (IPTG) to the culture.

4. The method of claim 1 , wherein the beta-lactamase polypeptide comprises the amino acid sequence of SEQ ID NO: 5.

5. The method of claim 1 , wherein the beta-lactamase polypeptide comprises the amino acid sequence of SEQ ID NO: 10 (P2A).

6. The method of claim 1 , wherein the expression vector comprises palindromic DNA looping.

7. The method of claim 1 , wherein the expression vector is capable of tightly controlled gene expression.

8. A method for the production of a beta-lactamase polypeptide in Escherichia coli ( E. coli ), comprising:

(a) providing a host E. coli cell transformed with an expression vector comprising a sequence encoding the beta-lactamase polypeptide;

(b) culturing the E. coli cell to induce expression of the beta-lactamase polypeptide in the cytoplasm; and

(c) recovering the beta-lactamase polypeptide from a cytoplasmic soluble fraction prepared from the E. coli cell; and

wherein the beta-lactamase polypeptide comprises an amino sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 10 and the method yields more than 15 grams of the beta-lactamase polypeptide per liter of culture,

wherein the host E. coli cell is selected from BL21 (DE3) or W3110, and

wherein the beta-lactamase polypeptide is not recovered or purified from a periplasmic fraction, a cell envelope fraction, a cytoplasmic insoluble fraction, an inclusion body, or an extracellular fraction of the E. coli cell.

Assignments (3)
CHANGE OF NAME Recorded Feb 28, 2023
From: SYNTHETIC BIOLOGICS, INC.
To: THERIVA BIOLOGICS, INC.
Reel/Frame 062824/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2021
From: HUBERT, STEVEN
To: SYNTHETIC BIOLOGICS, INC.
Reel/Frame 055954/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2017
From: BRISTOL, ANDREW; KALEKO, MICHAEL
To: SYNTHETIC BIOLOGICS, INC.
Reel/Frame 041384/0608 →
Continuity (2)
Provisional Application 62043360 · Aug 28, 2014
Related Publication 20180030458A1 · Feb 1, 2018